Furthermore, Midostaurin, inhibiting FLT3 mutations (being present in 30% of newly diagnosed adults) [21], Venetoclax, inhibiting the anti-apoptotic protein BCL2 [22], and Ivosidenib or Enasidenib, inhibiting IDH1 or IDH2 mutations (being present in 7–19% of AML patients) [3], have become crucial components in AML therapy. Here, FLT3 is linked to acute myeloid leukemia.